论文部分内容阅读
目的探讨左西孟旦与米力农治疗心力衰竭的效果对照。方法 76例心力衰竭患者,随机分为M组和Z组,各38例。M组用米力农治疗;Z组用左西孟旦治疗。比较两组患者心力衰竭治疗总有效率;治疗前后左室射血分数、左室舒张末和收缩末内径、血清氨基末端B型钠利尿肽前体(NTpro BNP)水平、药物不良反应率。结果 Z组患者心力衰竭治疗总有效率为97.37%,显著高于M组的78.95%,差异有统计学意义(P<0.05)。治疗前两组患者左室射血分数、左室舒张末和收缩末内径、血清NT-pro BNP水平比较,差异无统计学意义(P>0.05)。治疗后两组患者左室射血分数、左室舒张末和收缩末内径、血清NT-pro BNP水平显著优于治疗前,差异有统计学意义(P<0.05);且Z组左室射血分数升高幅度更大,左室舒张末和收缩末内径、血清NT-pro BNP水平降低幅度更大,差异有统计学意义(P<0.05)。Z组患者药物不良反应率为2.63%,显著低于M组的21.05%,差异有统计学意义(P<0.05)。结论左西孟旦与米力农治疗心力衰竭均有一定效果,但左西孟旦效果更好,可更好提高左室射血分数,延缓心室重构,且安全性更高,值得推广应用。
Objective To investigate the efficacy of levosimendan and milrinone in the treatment of heart failure. Methods 76 cases of heart failure patients were randomly divided into M group and Z group, 38 cases each. M group with Milrinone treatment; Z group with levosimendan treatment. The total effective rate of treatment of heart failure was compared between the two groups. The left ventricular ejection fraction, left ventricular end-diastolic diameter, end-systolic diameter, serum NT-BNP level and adverse drug reaction rate before and after treatment were compared. Results The total effective rate of treatment of heart failure in group Z was 97.37%, which was significantly higher than that in group M (78.95%), the difference was statistically significant (P <0.05). Left ventricular ejection fraction, left ventricular end-diastolic diameter and end-systolic diameter, serum NT-pro BNP levels in the two groups before treatment were not significantly different (P> 0.05). Left ventricular ejection fraction, end-diastolic and end-systolic diameters, serum NT-pro BNP levels in the two groups after treatment were significantly better than those before treatment (P <0.05), and the left ventricular ejection fraction Serum NT-pro BNP level decreased more significantly, and the difference was statistically significant (P <0.05). Adverse drug reaction rate in group Z was 2.63%, which was significantly lower than that in group M (21.05%), the difference was statistically significant (P <0.05). Conclusion Levosimendan and milrinone have some effects in the treatment of heart failure, but levosimendan is better, which can improve left ventricular ejection fraction, delay ventricular remodeling, and is more safe and worthy of promotion. .